Island Pharmaceuticals (ASX:ILA) Operating Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ILA Island Pharmaceuticals Ltd ASX:ILA
33 GF Score
Price A$0.47
! 2 Warning Signs
View Full Analysis

What is Island Pharmaceuticals Operating Margin %?

Island Pharmaceuticals ASX:ILA -2.08% 33 Operating Margin % is 0.00% as of Dec. 2025. GuruFocus rates ASX:ILA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 939 Biotechnology companies, Island Pharmaceuticals ranks worse than 87.65% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Island Pharmaceuticals's Operating Income for the six months ended in Dec. 2025 was A$-4.96 Mil. Island Pharmaceuticals's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Island Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Island Pharmaceuticals's Operating Margin % or its related term are showing as below:

ASX:ILA' s Operating Margin % Range Over the Past 10 Years
Min: -26336.36   Med: -3637.61   Max: -229.55
Current: -3637.61


ASX:ILA's Operating Margin % is ranked worse than
87.65% of 939 companies
in the Biotechnology industry
Industry Median: -86.77 vs ASX:ILA: -3637.61

Island Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Island Pharmaceuticals's Operating Income for the six months ended in Dec. 2025 was A$-4.96 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was A$-7.32 Mil.


Island Pharmaceuticals  (ASX:ILA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Island Pharmaceuticals Operating Margin % Related Terms


Island Pharmaceuticals Operating Margin % Historical Data

* Premium members only.

The historical data trend for Island Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Island Pharmaceuticals Operating Margin % Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Operating Margin %
0.00 0.00 -26,336.36 -229.55 -3,637.61

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:ILA vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Island Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Island Pharmaceuticals Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's Operating Margin % falls into.


ASX:ILA
33GF Score
Island Pharmaceuticals Ltd ASX:ILA
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Island Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Island Pharmaceuticals's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as

Operating Margin %=Operating Income (A: Jun. 2025 ) / Revenue (A: Jun. 2025 )
=-3.965 / 0.109
=-3,637.61 %

Island Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-4.956 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Island Pharmaceuticals (ASX:ILA) has a Operating Margin % of 0.00% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Island Pharmaceuticals and its competitors. According to the industry distribution chart, Island Pharmaceuticals ranks #823 out of 939 companies in the Biotechnology industry, placing it in the top 87.6%.
Is Island Pharmaceuticals' Operating Margin % too high?
Island Pharmaceuticals' current Operating Margin % is 0.00%. Based on the distribution chart, Island Pharmaceuticals ranks #823 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Island Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #823 out of 939 companies for Operating Margin %. This places Island Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Island Pharmaceuticals and its competitors. Island Pharmaceuticals's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Island Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current Operating Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Island Pharmaceuticals Business Description

Address c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
33GF Score

Get the complete analysis for ASX:ILA

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.47
Price